Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 23:2020:5347918.
doi: 10.1155/2020/5347918. eCollection 2020.

Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients with Severe Preeclampsia: A Randomized, Single-Blind, Controlled Trial

Affiliations

Efficacy of Diltiazem for the Control of Blood Pressure in Puerperal Patients with Severe Preeclampsia: A Randomized, Single-Blind, Controlled Trial

Gilberto Arias-Hernández et al. Int J Hypertens. .

Abstract

Background: Postpartum preeclampsia is a serious disease related to high blood pressure that occurs commonly within the first six days after delivery.

Objective: To evaluate if diltiazem improves blood pressure parameters in early puerperium patients with severe preeclampsia. Methodology. A randomized, single-blind longitudinal clinical trial of 42 puerperal patients with severe preeclampsia was carried out. Patients were randomized into two groups: the experimental group (n = 21) received diltiazem (60 mg) and the control group (n = 21) received nifedipine (10 mg). Both drugs were orally administered every 8 hours. Systolic, diastolic, and mean blood pressures as well as the heart rate were recorded and analyzed (two-way repeated measures ANOVA) at baseline and after 6, 12, 18, 24, 30, 36, 42, and 48 hours. Primary outcome measures were all the aforementioned blood pressure parameters. Secondary outcome measures included the number of hypertension and hypotension episodes along with the length of stay in the intensive care unit.

Results: No statistical differences were found between groups (diltiazem vs. nifedipine) regarding basal blood pressure parameters. Interarm differences in blood pressure (systolic, diastolic, and mean) and heart rate were statistically significant between treatment groups from 6 to 48 hours. Patients in the diltiazem group had lower blood pressure levels than patients in the nifedipine group. Significantly, patients who received diltiazem had fewer hypertension and hypotension episodes and stayed fewer days in the intensive care unit than those treated with nifedipine.

Conclusions: Diltiazem controlled arterial hypertension in a more effective and uniform manner in patients under study than nifedipine. Patients treated with diltiazem had fewer collateral effects and spent less time in the hospital. This trial is registered with NCT04222855.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
CONSORT chart for a trial of diltiazem and nifedipine for the control of blood pressure in puerperal patients with severe preeclampsia.
Figure 2
Figure 2
Systolic and diastolic blood pressure during 48 hours of observation, showing that both drugs reduced blood pressure. The decrease was greater with diltiazem. p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.
Figure 3
Figure 3
Mean blood pressure based on measurements of blood pressure with data sampled at 6-hour intervals for 48 hours, showing that both drugs lowered blood pressure. However, the reduction was greater with diltiazem. p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.
Figure 4
Figure 4
Average of heart rate during 48 hours of observation, showing distinct patterns for each drug with an increase and a decrease for patients with nifedipine and diltiazem, respectively. p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001. Values expressed as the means ± 2SEM were evaluated by repeated measures ANOVA.

Similar articles

Cited by

References

    1. Betrán A. P., Wojdyla D., Posner S. F., Gülmezoglu A. M. National estimates for maternal mortality: an analysis based on the WHO systematic review of maternal mortality and morbidity. BMC Public Health. 2005;5(1):p. 131. doi: 10.1186/1471-2458-5-131. - DOI - PMC - PubMed
    1. Bilano V. L., Ota E., Ganchimeg T., Mori R., Souza J. P. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low-and middle-income countries: a WHO secondary analysis. PLoS One. 2014;9(3) doi: 10.1371/journal.pone.0091198.e91198 - DOI - PMC - PubMed
    1. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia. Seminars in Perinatology. 2012;36(1):56–59. doi: 10.1053/j.semperi.2011.09.011. - DOI - PubMed
    1. Sibai B. M. Etiology and management of postpartum hypertension-preeclampsia. American Journal of Obstetrics and Gynecology. 2012;206(6):470–475. doi: 10.1016/j.ajog.2011.09.002. - DOI - PubMed
    1. Falco M. L., Sivanathan J., Laoreti A., Thilaganathan B., Khalil A. Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis. Ultrasound in Obstetrics & Gynecology. 2017;50(3):295–301. doi: 10.1002/uog.17494. - DOI - PubMed

Associated data

LinkOut - more resources